119 related articles for article (PubMed ID: 19149856)
1. Prevention of haemarthrosis in a murine model of acute joint bleeding.
Valentino LA; Hakobyan N; Kazarian T; Sorensen BB; Tranholm M
Haemophilia; 2009 Jan; 15(1):314-9. PubMed ID: 19149856
[TBL] [Abstract][Full Text] [Related]
2. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes.
Hakobyan N; Enockson C; Cole AA; Sumner DR; Valentino LA
Haemophilia; 2008 Jul; 14(4):804-9. PubMed ID: 18422608
[TBL] [Abstract][Full Text] [Related]
3. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency.
Valentino LA; Hakobyan N; Kazarian T; Jabbar KJ; Jabbar AA
Haemophilia; 2004 May; 10(3):280-7. PubMed ID: 15086328
[TBL] [Abstract][Full Text] [Related]
4. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.
Ovlisen K; Kristensen AT; Valentino LA; Hakobyan N; Ingerslev J; Tranholm M
J Thromb Haemost; 2008 Jun; 6(6):969-75. PubMed ID: 18363814
[TBL] [Abstract][Full Text] [Related]
5. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
[TBL] [Abstract][Full Text] [Related]
6. Synovitis in a murine model of human factor VIII deficiency.
Hakobyan N; Kazarian T; Valentino LA
Haemophilia; 2005 May; 11(3):227-32. PubMed ID: 15876267
[TBL] [Abstract][Full Text] [Related]
7. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
[TBL] [Abstract][Full Text] [Related]
8. Bleed volume of experimental knee haemarthrosis correlates with the subsequent degree of haemophilic arthropathy.
Vøls KK; Kjelgaard-Hansen M; Ley CD; Hansen AK; Petersen M
Haemophilia; 2019 Mar; 25(2):324-333. PubMed ID: 30648774
[TBL] [Abstract][Full Text] [Related]
9. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule.
Valentino LA; Cong L; Enockson C; Song X; Scheiflinger F; Muchitsch EM; Turecek PL; Hakobyan N
Haemophilia; 2015 Jan; 21(1):58-63. PubMed ID: 25459309
[TBL] [Abstract][Full Text] [Related]
10. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):772-9. PubMed ID: 27439658
[TBL] [Abstract][Full Text] [Related]
11. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
12. Exploring the biological basis of haemophilic joint disease: experimental studies.
Valentino LA; Hakobyan N; Enockson C; Simpson ML; Kakodkar NC; Cong L; Song X
Haemophilia; 2012 May; 18(3):310-8. PubMed ID: 22044636
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
Petrini P; Klementz G
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
[TBL] [Abstract][Full Text] [Related]
14. The impact of joint bleeding and synovitis on physical ability and joint function in a murine model of haemophilic synovitis.
Mejia-Carvajal C; Hakobyan N; Enockson C; Valentino LA
Haemophilia; 2008 Jan; 14(1):119-26. PubMed ID: 18184259
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
[TBL] [Abstract][Full Text] [Related]
16. Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice.
Nieuwenhuizen L; Roosendaal G; Coeleveld K; Lubberts E; Biesma DH; Lafeber FP; Schutgens RE
Thromb Haemost; 2013 Jul; 110(1):173-83. PubMed ID: 23677440
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.
Elm T; Karpf DM; Øvlisen K; Pelzer H; Ezban M; Kjalke M; Tranholm M
Haemophilia; 2012 Jan; 18(1):139-45. PubMed ID: 21771205
[TBL] [Abstract][Full Text] [Related]
18. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
Tcheng WY; Donkin J; Konzal S; Wong WY
Haemophilia; 2004 May; 10(3):295-8. PubMed ID: 15086331
[TBL] [Abstract][Full Text] [Related]
20. IL-1 beta, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis.
Øvlisen K; Kristensen AT; Jensen AL; Tranholm M
Haemophilia; 2009 May; 15(3):802-10. PubMed ID: 19444976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
